1.
J Eur Acad Dermatol Venereol
; 36(2): e94-e95, 2022 Feb.
Article
in English
| MEDLINE
| ID: mdl-34657332
2.
J Eur Acad Dermatol Venereol
; 35(8): e485-e487, 2021 Aug.
Article
in English
| MEDLINE
| ID: mdl-33872431
Subject(s)
Biological Products , COVID-19 , Psoriasis , Biological Therapy , Humans , Incidence , Prognosis , Psoriasis/drug therapy , Psoriasis/epidemiology , Retrospective Studies , SARS-CoV-2
3.
J Eur Acad Dermatol Venereol
; 34(8): e416-e418, 2020 Aug.
Article
in English
| MEDLINE
| ID: mdl-32176394
4.
J Eur Acad Dermatol Venereol
; 33(1): e7-e8, 2019 Jan.
Article
in English
| MEDLINE
| ID: mdl-29846974
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Interleukin-17/antagonists & inhibitors , Psoriasis/drug therapy , Adult , Antibodies, Monoclonal, Humanized/pharmacokinetics , Antibodies, Monoclonal, Humanized/pharmacology , Female , Humans , Male , Middle Aged , Retrospective Studies
5.
Br J Dermatol
; 180(1): 211-212, 2019 01.
Article
in English
| MEDLINE
| ID: mdl-30120892
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Long-Term Care , Psoriasis/drug therapy , Thalidomide/analogs & derivatives , Adult , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Diarrhea/chemically induced , Diarrhea/epidemiology , Female , Headache/chemically induced , Headache/epidemiology , Humans , Male , Middle Aged , Nausea/chemically induced , Nausea/epidemiology , Retrospective Studies , Thalidomide/administration & dosage , Thalidomide/adverse effects , Time Factors , Treatment Outcome , Weight Loss/drug effects
6.
J Eur Acad Dermatol Venereol
; 32(1): e32-e34, 2018 Jan.
Article
in English
| MEDLINE
| ID: mdl-28695989